1. At a Glance – Small IPO, Big Confidence
Accretion Nutraveda walks into the IPO market with a ₹24.77 Cr SME book-built issue, chest out, shoulders straight, priced confidently at ₹122–₹129. Pre-IPO market cap sits at ₹93.4 Cr, which already tells you one thing: this company thinks highly of itself.
Margins look juicy — EBITDA margin north of 23%, PAT margin ~16.6%, and ROE numbers so high they make traditional FMCG companies feel underdressed. But wait — retail investors need to cough up ₹2.58 lakh minimum, which automatically filters out casual “apply and forget” crowd.
This IPO is not begging for money. It’s demanding respect. The real question is: does the business deserve it?
2. Introduction – Welcome to the Ayurveda + PowerPoint Era
Accretion Nutraveda is a 2021-born company, which means it learnt Ayurveda from textbooks, not from grandma’s rasoi. It positions itself as a CDMO (Contract Development & Manufacturing Organisation) — a fancy way of saying “we manufacture for others and don’t spend money on Instagram influencers.”
The company sits at the intersection of Ayurveda + Nutraceuticals, which is currently one of the most crowded junctions in Indian healthcare. Everyone from startups to baba-backed brands is selling powders, capsules, oils, and promises.
Nutraveda says: “Relax. We don’t sell dreams. We manufacture them for brands.”
Interesting pitch. Let’s see what’s under the hood.
3. Business Model – WTF Do They Even Do?
Accretion Nutraveda manufactures Ayurvedic and nutraceutical products in almost every dosage form you can imagine:
- Tablets & capsules
- Syrups & oral liquids
- Powders & oils
- Creams, gels, balms (external use gang)
But the twist is — they are not a consumer brand.
They operate as a CDMO, meaning:
- Clients give formulation specs
- Nutraveda manufactures
- Clients sell under their own brand
- Nutraveda smiles quietly and counts margins
This model avoids:
- Advertising burns
- Distribution wars
- Celebrity
